Korro Reports First Quarter 2024 Financial Results and Appointment of Kemi Olugemo, M.D. as Chief Medical Officer
Korro Bio, Inc. (KRRO)
Company Research
Source: GlobeNewswire
On track for regulatory filing for First-in-Human (FIH) study of KRRO-110 in patients with Alpha-1 Antitrypsin Deficiency (AATD) anticipated in the second half of 2024 Further strengthened balance sheet with closing of $70.0 million private placement (PIPE) on April 22, 2024, with cash and cash equivalents of approximately $206 million at close Cash runway into second half of 2026 to fund anticipated interim readout of KRRO-110 in the second half of 2025 and FIH study completion in 2026 Appointed Kemi Olugemo, M.D., FANN as Chief Medical Officer CAMBRIDGE, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, today reported financial results for the first quarter of 2024 and provided an update on its recent progress and anticipated milestones. "Korro’s first quarter performan
Show less
Read more
Impact Snapshot
Event Time:
KRRO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KRRO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KRRO alerts
High impacting Korro Bio, Inc. news events
Weekly update
A roundup of the hottest topics
KRRO
News
- Korro Bio, Inc. (NASDAQ: KRRO) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $95.00 price target on the stock.MarketBeat
- Korro Bio, Inc. (NASDAQ: KRRO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $100.00 price target on the stock.MarketBeat
- Korro Bio Announces Collaboration with Novo Nordisk to Develop Two Therapeutic CandidatesGlobeNewswire
- Korro to Participate in Upcoming Investor ConferencesGlobeNewswire
- Korro Announces Addition of Industry Veteran Katharine Knobil to and Resignation of David Lucchino From Its Board of DirectorsGlobeNewswire
KRRO
Earnings
- 8/13/24 - Miss
KRRO
Sec Filings
- 9/16/24 - Form 424B3
- 9/16/24 - Form 424B3
- 9/16/24 - Form 8-K
- KRRO's page on the SEC website